First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

BACKGROUND: This is the first-in-human study of novel anti-angiopoietin-2 (Ang-2) monoclonal antibody LY3127804 as monotherapy and in combination with ramucirumab in advanced solid tumours. METHODS: Patients received intravenous LY3127804 monotherapy (4, 8, 12, 16, 20 and 27 mg/kg) in part A; LY3127...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Liberal, Juan, Hollebecque, Antoine, Aftimos, Philippe, Jungels, Christiane, Martin-Romano, Patricia, Rodon, Jordi, Kremer, Jill Dolores, Zhang, Wei, Bendell, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555513/
https://www.ncbi.nlm.nih.gov/pubmed/32741971
http://dx.doi.org/10.1038/s41416-020-1011-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555513/
https://www.ncbi.nlm.nih.gov/pubmed/32741971
http://dx.doi.org/10.1038/s41416-020-1011-7

Ejemplares similares